These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 37984551)
21. [Clinical characteristics and genetic profile of complement system in renal thrombotic microangiopathy in patients with severe forms of arterial hypertension]. Akaeva MI; Kozlovskaya NL; Bobrova LA; Vorobyeva OA; Stoliarevich ES; Shatalov PA; Smirnova TV; Anan'eva AO Ter Arkh; 2024 Jul; 96(6):571-579. PubMed ID: 39106497 [TBL] [Abstract][Full Text] [Related]
22. Eculizumab in secondary atypical haemolytic uraemic syndrome. Cavero T; Rabasco C; López A; Román E; Ávila A; Sevillano Á; Huerta A; Rojas-Rivera J; Fuentes C; Blasco M; Jarque A; García A; Mendizabal S; Gavela E; Macía M; Quintana LF; María Romera A; Borrego J; Arjona E; Espinosa M; Portolés J; Gracia-Iguacel C; González-Parra E; Aljama P; Morales E; Cao M; Rodríguez de Córdoba S; Praga M Nephrol Dial Transplant; 2017 Mar; 32(3):466-474. PubMed ID: 28339660 [TBL] [Abstract][Full Text] [Related]
23. Thrombotic Microangiopathy Following Pediatric Autologous Hematopoietic Cell Transplantation: A Report of Significant End-Organ Dysfunction in Eculizumab-Treated Survivors. Schoettler M; Lehmann L; Li A; Ma C; Duncan C Biol Blood Marrow Transplant; 2019 May; 25(5):e163-e168. PubMed ID: 30639820 [TBL] [Abstract][Full Text] [Related]
24. Thrombotic microangiopathy after kidney transplantation: Analysis of the Brazilian Atypical Hemolytic Uremic Syndrome cohort. Nga HS; Palma LMP; Ernandes Neto M; Fernandes-Charpiot IMM; Garcia VD; Kist R; Miranda SMC; Macedo de Souza PA; Pereira GM; de Andrade LGM PLoS One; 2021; 16(11):e0258319. PubMed ID: 34748552 [TBL] [Abstract][Full Text] [Related]
26. Thrombotic microangiopathy caused by methionine synthase deficiency: diagnosis and treatment pitfalls. Vaisbich MH; Braga A; Gabrielle M; Bueno C; Piazzon F; Kok F Pediatr Nephrol; 2017 Jun; 32(6):1089-1092. PubMed ID: 28210839 [TBL] [Abstract][Full Text] [Related]
27. The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab. Tanaka K; Adams B; Aris AM; Fujita N; Ogawa M; Ortiz S; Vallee M; Greenbaum LA Pediatr Nephrol; 2021 Apr; 36(4):889-898. PubMed ID: 33048203 [TBL] [Abstract][Full Text] [Related]
28. The use of eculizumab in gemcitabine induced thrombotic microangiopathy. Krishnappa V; Gupta M; Shah H; Das A; Tanphaichitr N; Novak R; Raina R BMC Nephrol; 2018 Jan; 19(1):9. PubMed ID: 29329518 [TBL] [Abstract][Full Text] [Related]
29. Eculizumab as Salvage Treatment for Thrombotic Microangiopathy After Lung Transplantation. Trujillo H; Huerta A; Alonso R; Serrano ML; Aguilar M; Morales E; Cavero T Clin Transplant; 2024 Sep; 38(9):e15443. PubMed ID: 39207183 [TBL] [Abstract][Full Text] [Related]
30. Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation. Acosta-Medina AA; Moyer AM; Go RS; Willrich MAV; Fervenza FC; Leung N; Bourlon C; Winters JL; Spears GM; Bryant SC; Sridharan M Blood Adv; 2023 Feb; 7(3):340-350. PubMed ID: 35533258 [TBL] [Abstract][Full Text] [Related]
31. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series. Duineveld C; Verhave JC; Berger SP; van de Kar NCAJ; Wetzels JFM Am J Kidney Dis; 2017 Dec; 70(6):770-777. PubMed ID: 28821363 [TBL] [Abstract][Full Text] [Related]
32. Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a Global aHUS Registry analysis. Fakhouri F; Scully M; Ardissino G; Al-Dakkak I; Miller B; Rondeau E J Nephrol; 2021 Oct; 34(5):1581-1590. PubMed ID: 33826112 [TBL] [Abstract][Full Text] [Related]
33. Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC. de Fontbrune FS; Galambrun C; Sirvent A; Huynh A; Faguer S; Nguyen S; Bay JO; Neven B; Moussi J; Simon L; Xhaard A; Resche-Riggon M; O'Meara A; Fremeaux-Bacchi V; Veyradier A; Socié G; Coppo P; de Latour RP Transplantation; 2015 Sep; 99(9):1953-9. PubMed ID: 25651309 [TBL] [Abstract][Full Text] [Related]
34. Differential contribution of C5aR and C5b-9 pathways to renal thrombic microangiopathy and macrovascular thrombosis in mice carrying an atypical hemolytic syndrome-related factor H mutation. Ueda Y; Miwa T; Ito D; Kim H; Sato S; Gullipalli D; Zhou L; Golla M; Song D; Dunaief JL; Palmer MB; Song WC Kidney Int; 2019 Jul; 96(1):67-79. PubMed ID: 30910380 [TBL] [Abstract][Full Text] [Related]
35. [Atypical hemolytic uremic syndrome (aHUS): new insights into pathogenesis leading to novel therapeutic approaches]. Kistler AD Praxis (Bern 1994); 2016 Mar; 105(7):389-96. PubMed ID: 27005733 [TBL] [Abstract][Full Text] [Related]
36. [Nephrological aspects of complement-mediated thrombotic microangiopathy]. Smirnov AV; Karunnaya AV; Dobronravov VA Ter Arkh; 2017; 89(6):34-40. PubMed ID: 28745687 [TBL] [Abstract][Full Text] [Related]
37. Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review. de Holanda MI; Pôrto LC; Wagner T; Christiani LF; Palma LMP Clin Rheumatol; 2017 Dec; 36(12):2859-2867. PubMed ID: 28905254 [TBL] [Abstract][Full Text] [Related]
38. Clinical efficacy and safety of switching from eculizumab to ravulizumab in adult patients with aHUS- real-world data. Schönfelder K; Kühne L; Schulte-Kemna L; Kaufeld J; Rohn H; Kribben A; Schröppel B; Brinkkötter PT; Gäckler A BMC Nephrol; 2024 Jun; 25(1):202. PubMed ID: 38898427 [TBL] [Abstract][Full Text] [Related]
39. Eculizumab treatment of thrombotic microangiopathy in a patient with ulcerative colitis. Øzbay LA Clin J Gastroenterol; 2020 Jun; 13(3):344-348. PubMed ID: 31612381 [TBL] [Abstract][Full Text] [Related]
40. Eculizumab for Severe Thrombotic Microangiopathy Secondary to Surgical Invasive Stress and Bleeding. Fujita Y; Terashita M; Yazawa M; Yamasaki Y; Imamura T; Kibayashi J; Sawai T; Hidaka Y; Ohtani K; Inoue N; Shibagaki Y Intern Med; 2020; 59(1):93-99. PubMed ID: 31902910 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]